Neurogenic Technologies, Inc.

Neurogenic Technologies, Inc. (NTI), was established in 1999 to develop innovative medical devices that bridge the gap between highly sophisticated scientific advances and everyday clinical use. By adapting the knowledge acquired by the world’s foremost scientists and making it available for Neurologists, Physical and Occupational Therapists, Athletic Trainers, Orthopedic Surgeons and others, NTI is helping to improve clinical treatment efficacy and scientific data collection. The technology for NTI’s Myotonometer® was developed by a collaborative effort between scientists, physicians and engineers employed within the Russian Aerospace Industry and Dr. Charles T. Leonard, Professor and Director of The Motor Control Research Laboratory at The University of Montana. The device was initially intended to assess the effects of weightlessness on muscle tone. During testing it became apparent that the device had many broad applications that included sports medicine, fitness, industrial medicine, neurology and physical rehabilitation.

Following a series of clinical studies which verified the Myotonometer’s validity and reliability with patient populations, the hardware and software were trademarked and granted a U.S. patent. The latest version of the Myotonometer is highly accurate, easy to calibrate, works with user-friendly computational software and is now ready for commercial use.

Principals

Charles T. Leonard, PT, PhD.
Founder, Director of Research & Development
Neurogenic Technologies, Inc.

Kenneth Runnion, MBA
CEO
Neurogenic Technologies, Inc.

Eugene Mikhailenok, M.D., PhD.
Science Advisory Board
Neurogenic Technologies, Inc.

Olga Voronina, PhD.
Science Advisory Board
Neurogenic Technologies, Inc.